Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Free Cash Flow (2020 - 2025)

Tango Therapeutics has reported Free Cash Flow over the past 6 years, most recently at -$30.5 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$30.5 million for Q4 2025, up 16.93% from a year ago — trailing twelve months through Dec 2025 was -$139.9 million (down 5.81% YoY), and the annual figure for FY2025 was -$139.9 million, down 5.81%.
  • Free Cash Flow for Q4 2025 was -$30.5 million at Tango Therapeutics, up from -$30.9 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TNGX hit a ceiling of -$7.8 million in Q2 2021 and a floor of -$41.7 million in Q1 2025.
  • Median Free Cash Flow over the past 5 years was -$30.7 million (2025), compared with a mean of -$28.3 million.
  • Biggest five-year swings in Free Cash Flow: crashed 24387400.0% in 2021 and later grew 26.95% in 2023.
  • Tango Therapeutics' Free Cash Flow stood at -$16.6 million in 2021, then crashed by 110.39% to -$35.0 million in 2022, then rose by 25.14% to -$26.2 million in 2023, then tumbled by 40.32% to -$36.8 million in 2024, then rose by 16.93% to -$30.5 million in 2025.
  • The last three reported values for Free Cash Flow were -$30.5 million (Q4 2025), -$30.9 million (Q3 2025), and -$36.7 million (Q2 2025) per Business Quant data.